I say take the party into the 90s. I like higher floors. Then penthouse. Not much happening in the 80s imo

Old news. Try to stay awake

More tidbits. Folks should really take the time to read 10Q if you’re serious about this ground floor opportunity. If just flippin for beer money, go enjoy your cold one

From the 10Q

She needs to clear 50MA. Then fun begins. $DPWW

Assets went up. Liabilities went down. Net income vs net loss. I don’t know if there is anything more I’d ask my 2¢. Mkt sleeping on this one for sure. $DPWW

Added some more today. Last 6 months: Net income of $1M vs loss of $8M a year back. Boom. $DPWW

GM $DPWW
Excited about this week here. Chart shaping up nicely. Oct 17 in stone throw. Co working on executing their strategy. News will follow to fill us in imo.

If trader has fomo they would buy a stock not sit on sidelines. Your definition of fomo is not correct imo

Suspect be pretty soon once we get some volume

A full house in iHub is always so much more fun. We got here a bit early before the gang arrives

Nice way to wake up Saturday morning. Traders and investors likely doing dd this weekend on this little gem with tiny float and yuuuggge potential. REAL COMPANY with REAL REVS. Big things ahead imo $DPWW

You’re right señor buster. Great movie. It was just like watching the 8s and 9s being eaten up here at $DPWW LMAO.

Back at it next week.

Lots of eyes on her over the weekend. $DPWW

Going to go watch the recent MI movie with wifey. Hold the fort captain

I’ve got 5 years

Csti with a milli bid on 9s. Nice

Thanks for the suggestion. I sucked them up myself. $DPWW

I like how you think captain.

Boy they are beautiful. And I’ve heard they have deep pockets

Great call captain. Surgical precision from a sailor. Now that’s skill

Beautiful hammer on weekly with volume. Bottom is in. We move up from here. Oct 17 is around the corner. Are we going to have a store north of the border? Not too far from Seattle if you ask me. Boom! $DPWW

And of course some short minded flipper is now on 95 with 100K. Making beer money for Friday night when they could hold and buy THE WHOLE brewery down the road. $DPWW

That OTCX dude must be in a hole for all those 7s he sold us. Now he is on the bid let him chase what a tool $DPWW

Bought me some 9s. They’re yummier than them 8s. Try some $DPWW

She is thinnnnnn like an anorexic hooker. Pennyland coming weeeeeeeeeeeeeeéêèëeee $DPWW

RSI gaining strength and other indicators curling again. Are we building a higher base? Sure think so $DPWW

$1.80-$1.50 coming imo ??

Akari Announces First Quarter 2018 Financial Results and Update on its Growing Pipeline of Phase II and Phase III Clinical Trials
August 17, 2018
Opened three clinical trials in 2018
Trials in which complement dysregulation is the primary disease driver
CAPSTONE, the Phase III trial in naïve paroxysmal nocturnal hemoglobinuria (PNH), in which patient treatment has commenced
Phase II U.S. trial for PNH patients resistant to treatment with Soliris where a patient is now being treated
Phase II trial in atypical haemolytic syndrome (aHUS) which opened Q4 2017
Trials focused on a separate group of diseases mediated by both the complement and leukotriene pathways
Phase II trial in bullous pemphigoid (BP), recently opened with data expected Q1 2019
Phase I/II trial in atopic keratoconjunctivitis (AKC) expected to commence Q3 2018, with data anticipated Q1 2019
NEW YORK and LONDON, Aug. 17, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announced its financial results for the first quarter ended March 31, 2018 and highlights its pipeline of Phase II and Phase III clinical trials.

“We are excited by the range of clinical opportunities that we are currently exploring. We look forward to providing initial clinical data from these trials starting in the fourth quarter of 2018,” commented Clive Richardson, acting Chief Executive Officer of Akari Therapeutics. “Akari does not intend to develop all of these programs through to commercialization on its own but rather, intends to partner one or more of its programs. To that end, a robust business development program has been in progress since early 2018 led by Mike Grissinger, an Akari non-executive director and pharmaceutical industry veteran who spent 22 years at Johnson & Johnson in business development leadership roles.”

Clinical Development Programs Highlights

Akari’s clinical program is divided into two separate workstreams targeting two different sets of clinical conditions. One group of diseases is where the combined inhibition of the complement and leukotriene pathways provides a potential new treatment solution for a wide range of currently poorly treated orphan inflammatory conditions. The second group of diseases are those where complement dysregulation is the primary driver.

Dual C5 and Leukotriene B4 Program

The increasing recognition that LTB4 may combine with complement dysregulation in the etiology of many autoimmune and autoinflammatory conditions has focused Akari’s clinical development on a number of poorly treated conditions where Coversin’s dual C5 and LTB4 binding provides a potential novel therapeutic solution. These programs include bullous pemphigoid (BP), an inflammatory skin disease in which current treatment is limited to steroids, and immunosuppressants and atopic keratoconjunctivitis (AKC), an eye surface inflammatory disease which can lead to permanent vision loss and for which there are few effective treatment options. Both are rare conditions for which Akari is seeking orphan designation.

Complement Program

Patient treatment in CAPSTONE, the Phase III trial in naïve PNH patients, has commenced. We anticipate introducing a new pen injector in 2019 to facilitate patient use which will accommodate a week’s supply of medication. Within the program to treat patients with a polymorphism that makes them resistant to treatment with Soliris, Akari recently began treating a second PNH patient under an investigational new drug application (IND) in the U.S. This patient has responded well (LDH <1.5xULN at day 28). In all, three Soliris resistant patients have now been treated with Coversin; two with PNH and a third with a thrombotic microangiopathy (TMA). All PNH patients remaining on treatment have the option of entering into the Akari long term safety program. Nine PNH patients have been treated in aggregate for over 11 patient years with no drug related SAEs to date.

Akari has also opened a clinical program targeting thrombotic microangiopathies (TMA) including atypical haemolytic syndrome (aHUS). We expect to provide an update on Akari’s TMA program in Q4 2018.

First Quarter 2018 Financial Results

As of March 31, 2018, the Company had cash of $23.8 million, as compared to cash of $28.1 million as of December 31, 2017.
Operating expenses, which include research and development (R&D) expenses and general and administrative (G&A) expenses, were $4.3 million in the first quarter of 2018, as compared to $8.3 million in the same quarter the prior year.
R&D expenses in the first quarter of 2018 were $1.0 million, as compared to $6.0 million in the same quarter the prior year. The decrease was due primarily to an R&D tax credit of approximately $3.8 million received in the first quarter of 2018 and lower manufacturing costs of $1.4 million associated with Coversin clinical trial material, offset by an increase in clinical trial expenses.
G&A expenses in the first quarter of 2018 were $3.3 million, as compared to $2.3 million in the same quarter last year. This increase was due primarily to higher legal, accounting and other professional service fees.
Total other income for the first quarter of 2018 was $3.0 million, as compared to total other expense of $4.3 million in the first quarter of 2017. This change was primarily attributed to $2.9 million of other income in the first quarter of 2018 compared to $4.3 million of other expense in the same period in 2017 related in both instances to the change in fair value of the stock option and warrant liabilities.
Net loss for the first quarter of 2018 was $1.3 million, compared to a net loss of $12.6 million for the same period in 2017. This year over year decrease in net loss was due primarily to lower R&D expenses in the first quarter of 2018 when compared to the same period in 2017.
About Akari Therapeutics

Dr Raymond Prudo
Executive Chairman
Akari Therapeutics Plc
75 Wimpole Street, London, W1G 9RT

Tel +44 (0) 20 3865 7798

Email ray.prudo@akaritx.com
PA anjala.aoulik@akaritx.com
Web www.akaritx.com

New York office
Akari Therapeutics Plc
24 W 40th Street, 8th Floor
New York, NY 10018

Good points. I won’t be surprised if all these bozos get thrown into jail one day. What infuriates me is they’ll blown several accounts on the way and a lot of idiots especially on StockTwits are in pure denial that they’re upside down hundreds of thousands of dollars in this shxthole called $DPW

Why did he guide down by $10M for revs (reason provided was depressed crypto prices) when they did only $700K in mining this past qtr. doesn’t add up imo (like a lot of other things here). $DPW

I got a small fill at 63s today.

$JRSH strong guidance. Q2 rev guide is ~2x Q1 revs. Wow.

Like I had said https://investorshub.advfn.com/boards/m_read_msg.aspx?message_id=142836764

So I fooled around a little bit today evening to see what other MJ plays are out there using the very solid Trading View screener. I didn't want to get a huge list of MJ plays but just a handful of them which have similar opportunity in terms of small market cap and revenue generating play like our little gem here $DPWW. I played with some filters which I am happy to share if anyone has any interest but based on the mkt cap filter of <$5M while at the same time having annual revs of > $1M, guess how many plays showed up from the MJ world. ONE stinking play ---> $DPWW!



This is why I said this is a multi-month swing for me. With the solid management team we have on board, the opportunity of gains here is just bigly IMO. If anyone has interest in looking at other tickers, I have uploaded a copy of my screen results at this link - https://docs.google.com/spreadsheets/d/1iwomGgRXYYtZ5ysIAOV7CGJA50aN3gbDqX6eKFekcXc/edit?usp=sharing

Cheers,
Roger

He has been right so far. At same time I truly hope the trade works out for you. I know you’re holding a heavy bag here. Right now I don’t have a position but always watching this one. $SNGX

And he is back